Lyon, France, May 15, 2018 – Theranexus, a clinical stage innovative biopharmaceutical company that focuses on the treatment of neurological diseases, today announces its cash position as at 31 March 2018.
Cash and cash equivalents at 31 March 2018 amounted to €16,172,000 versus €942,000 at 31 March 2017 (the Company's IPO took place in October 2017). As a reminder, cash and cash equivalents stood at €18,226,000 at 31 December 2017.
| |ABOUT THERANEXUS
Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role played by non-neuronal cells (also known as “glial cells”) in the body's response to psychotropic drugs (which target the neurons). The company is a pioneer in the design and development of drug candidates affecting the interaction between neurons and glial cells. The unique, patented technology used by Theranexus is designed to improve the efficacy of psychotropic drugs already approved and on the market, by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market.
The proprietary, adaptable Theranexus platform can generate different proprietary drug candidates offering high added-value for multiple indications.
Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).
More information at: www.theranexus-bourse.com